{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:07:53Z","timestamp":1789067273607,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University","award":["PY202424"],"award-info":[{"award-number":["PY202424"]}]},{"name":"Jangsu Province Hlospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project","award":["JSPH-MB-2023-12"],"award-info":[{"award-number":["JSPH-MB-2023-12"]}]},{"name":"Development Cancer for Medical Science & Technology National Health Commission of the People\u2019s Republic of China \"Innovative Drug post-marketing Clinical Research Research Project\"","award":["WKZX2024CX102203"],"award-info":[{"award-number":["WKZX2024CX102203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14601-2","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:56:49Z","timestamp":1753365409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting"],"prefix":"10.1186","volume":"25","author":[{"given":"Qianqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"1","key":"14601_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"14601_CR2","first-page":"113","volume":"11","author":"I Gounaris","year":"2010","unstructured":"Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP. 2010;11(2):113\u201323.","journal-title":"JOP"},{"issue":"23","key":"14601_CR3","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14601_CR4","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14601_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jjco\/hyq167","volume":"41","author":"T Matsuda","year":"2011","unstructured":"Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T. Research group of Population-Based Cancer registries of J: Population-based survival of cancer patients diagnosed between 1993 and 1999 in japan: a chronological and international comparative study. Jpn J Clin Oncol. 2011;41(1):40\u201351.","journal-title":"Jpn J Clin Oncol"},{"key":"14601_CR6","doi-asserted-by":"crossref","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"issue":"15","key":"14601_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25(15):1960\u20136.","journal-title":"J Clin Oncol"},{"issue":"18","key":"14601_CR8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"19","key":"14601_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"10409","key":"14601_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"issue":"10018","key":"14601_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"4","key":"14601_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/bjc.2016.436","volume":"116","author":"T Ioka","year":"2017","unstructured":"Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, et al. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017;116(4):464\u201371.","journal-title":"Br J Cancer"},{"key":"14601_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2021.08.002","volume":"157","author":"SI Go","year":"2021","unstructured":"Go SI, Lee SC, Bae WK, Zang DY, Lee HW, Jang JS, Ji JH, Kim JH, Park S, Sym SJ, et al. Modified folfirinox versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: a randomised controlled trial (MPACA-3). Eur J Cancer. 2021;157:21\u201330.","journal-title":"Eur J Cancer"},{"issue":"1","key":"14601_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01948-4","volume":"9","author":"J Cui","year":"2024","unstructured":"Cui J, Qin S, Zhou Y, Zhang S, Sun X, Zhang M, Cui J, Fang W, Gu K, Li Z, et al. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct Target Ther. 2024;9(1): 248.","journal-title":"Signal Transduct Target Ther"},{"key":"14601_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104386","volume":"201","author":"BS Chen","year":"2024","unstructured":"Chen BS, Chan SY, Bteich F, Kuang C, Meyerhardt JA, Ma KS. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024;201: 104386.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"14601_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267\u201377.","journal-title":"JAMA"},{"issue":"1","key":"14601_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-024-01613-x","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang J, Yang J, Narang A, He J, Wolfgang C, Li K, Zheng L. Consensus, debate, and prospective on pancreatic cancer treatments. J Hematol Oncol. 2024;17(1):92.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"14601_CR18","first-page":"799","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Guo X, Xu P, Song Y, Huang J, Chen X, Zhu W, Hao J, Gao S. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Cancer Biol Med. 2024;21(9):799\u2013812.","journal-title":"Cancer Biol Med"},{"issue":"11","key":"14601_CR19","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676\u201381.","journal-title":"Eur J Cancer"},{"issue":"1","key":"14601_CR20","doi-asserted-by":"publisher","first-page":"19399","DOI":"10.1038\/s41598-023-46924-0","volume":"13","author":"M Fukahori","year":"2023","unstructured":"Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, et al. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Sci Rep. 2023;13(1):19399.","journal-title":"Sci Rep"},{"key":"14601_CR21","doi-asserted-by":"publisher","first-page":"175883592413098","DOI":"10.1177\/17588359241309828","volume":"17","author":"R Alvarez-Gallego","year":"2025","unstructured":"Alvarez-Gallego R, Pazo-Cid R, Lopez de San Vicente B, Macarulla T, Martinez E, Garicano F, Hernandez I, Granja M, Ghanem I, Martinez J, et al. Real-world effectiveness and safety of second- or third-line pegylated liposomal Irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain. Ther Adv Med Oncol. 2025;17:17588359241309828.","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"14601_CR22","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1002\/cam4.6111","volume":"12","author":"L Procaccio","year":"2023","unstructured":"Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, et al. The role of nanoliposomal Irinotecan plus fluorouracil\/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 2023;12(13):14337\u201345.","journal-title":"Cancer Med"},{"issue":"1","key":"14601_CR23","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1038\/s41598-024-65689-8","volume":"14","author":"T Shibuki","year":"2024","unstructured":"Shibuki T, Otsuka T, Shimokawa M, Nakazawa J, Arima S, Fukahori M, Miwa K, Okabe Y, Koga F, Ueda Y, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine\/nab-paclitaxel. Sci Rep. 2024;14(1):16906.","journal-title":"Sci Rep"},{"issue":"32","key":"14601_CR24","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, et al. Pancreox: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14601_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00432-024-05827-x","volume":"150","author":"DP Modest","year":"2024","unstructured":"Modest DP, Heinemann V, Schutt P, Angermeier S, Haberkorn M, Waidmann O, Graeven U, Wille K, Kunzmann V, Henze L, et al. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU\/LV\/irinotecan (FOLFIRI) vs. 5-FU\/LV\/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). J Cancer Res Clin Oncol. 2024;150(7):332.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"14601_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","volume":"81","author":"M Ozaka","year":"2018","unstructured":"Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, et al. A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2018;81(6):1017\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"14601_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2016.45","volume":"114","author":"SM Stein","year":"2016","unstructured":"Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):737\u201343.","journal-title":"Br J Cancer"},{"issue":"1","key":"14601_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12885-020-06945-8","volume":"20","author":"M Sawada","year":"2020","unstructured":"Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer. 2020;20(1):449.","journal-title":"BMC Cancer"},{"issue":"6","key":"14601_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.pan.2022.06.004","volume":"22","author":"S Tezuka","year":"2022","unstructured":"Tezuka S, Ueno M, Kobayashi S, Hamaguchi T, Yamachika Y, Oishi R, Nagashima S, Fukushima T, Morimoto M, Shin M. Nal-IRI\/5-FU\/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: a single center retrospective study. Pancreatology. 2022;22(6):789\u201396.","journal-title":"Pancreatology"},{"issue":"12","key":"14601_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1080\/0284186X.2021.1973680","volume":"60","author":"A Ekstrom","year":"2021","unstructured":"Ekstrom A, Brun E, Eberhard J, Segerlantz M. Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer. Acta Oncol. 2021;60(12):1580\u20138.","journal-title":"Acta Oncol"},{"issue":"12","key":"14601_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.6004\/jnccn.2023.7065","volume":"21","author":"C Neuzillet","year":"2023","unstructured":"Neuzillet C, Bouche O, Tournigand C, Chibaudel B, Bauguion L, Bengrine-Lefevre L, Lopez-Trabada Ataz D, Mabro M, Metges JP, Pere-Verge D, et al. Effect of adapted physical activity in patients with advanced pancreatic cancer: the APACaP GERCOR randomized trial. J Natl Compr Canc Netw. 2023;21(12):1234\u201342. e1217.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"14601_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic Cancer immunotherapy. Cancer Cell. 2020;38(6):788\u2013802.","journal-title":"Cancer Cell"},{"issue":"8","key":"14601_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","journal-title":"J Immunother"},{"issue":"8","key":"14601_CR34","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","volume":"30","author":"Q Fu","year":"2023","unstructured":"Fu Q, Chen Y, Huang D, Guo C, Zhang X, Xiao W, Xue X, Zhang Q, Li X, Gao S, et al. Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial. Ann Surg Oncol. 2023;30(8):5071\u201380.","journal-title":"Ann Surg Oncol"},{"key":"14601_CR35","doi-asserted-by":"crossref","unstructured":"Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A 3rd, Mulcahy M. Ipilimumab and gemcitabine for advanced pancreatic cancer: A phase Ib study. Oncologist. 2020;25(5):e808\u201315.","DOI":"10.1634\/theoncologist.2019-0473"},{"issue":"4","key":"14601_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"key":"14601_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00252","volume":"7","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Yedururi S, Huse J, Chinapuvvula SV, Wu J, Subbiah V. Exceptional responses to Selpercatinib in RET fusion-driven metastatic pancreatic cancer. JCO Precis Oncol. 2023;7: e2300252.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"14601_CR38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21(4):531\u201340.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14601_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388(1):33\u201343.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14601-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:49:51Z","timestamp":1757281791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14601"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14601-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the First Affiliated Hospital of Nanjing Medical University Ethics Committee and complied with the ethical standards of the Declaration of Helsinki. All participants gave their written informed consent at registry inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1209"}}